These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 19365401)

  • 21. Triple Oral Therapy Versus Antitumor Necrosis Factor Plus Methotrexate (MTX) in Patients with Rheumatoid Arthritis and Inadequate Response to MTX: A Systematic Literature Review.
    Mary J; De Bandt M; Lukas C; Morel J; Combe B
    J Rheumatol; 2017 Jun; 44(6):773-779. PubMed ID: 28412710
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The influence of a polymorphism at position -857 of the tumour necrosis factor alpha gene on clinical response to etanercept therapy in rheumatoid arthritis.
    Kang CP; Lee KW; Yoo DH; Kang C; Bae SC
    Rheumatology (Oxford); 2005 Apr; 44(4):547-52. PubMed ID: 15695296
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials.
    Bongartz T; Sutton AJ; Sweeting MJ; Buchan I; Matteson EL; Montori V
    JAMA; 2006 May; 295(19):2275-85. PubMed ID: 16705109
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A single nucleotide polymorphism of TRAF1 predicts the clinical response to anti-TNF treatment in Japanese patients with rheumatoid arthritis.
    Nishimoto T; Seta N; Anan R; Yamamoto T; Kaneko Y; Takeuchi T; Kuwana M
    Clin Exp Rheumatol; 2014; 32(2):211-7. PubMed ID: 24321457
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Good clinical response, remission, and predictors of remission in rheumatoid arthritis patients treated with tumor necrosis factor-alpha blockers: the GISEA study.
    Mancarella L; Bobbio-Pallavicini F; Ceccarelli F; Falappone PC; Ferrante A; Malesci D; Massara A; Nacci F; Secchi ME; Manganelli S; Salaffi F; Bambara ML; Bombardieri S; Cutolo M; Ferri C; Galeazzi M; Gerli R; Giacomelli R; Grassi W; Lapadula G; Cerinic MM; Montecucco C; Trotta F; Triolo G; Valentini G; Valesini G; Ferraccioli GF;
    J Rheumatol; 2007 Aug; 34(8):1670-3. PubMed ID: 17611987
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Polymorphism in the tumor necrosis factor-alpha gene promoter is associated with severity of rheumatoid arthritis in the Czech population.
    Nemec P; Pavkova-Goldbergova M; Stouracova M; Vasku A; Soucek M; Gatterova J
    Clin Rheumatol; 2008 Jan; 27(1):59-65. PubMed ID: 17562093
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Increased pretreatment serum IFN-β/α ratio predicts non-response to tumour necrosis factor α inhibition in rheumatoid arthritis.
    Wampler Muskardin T; Vashisht P; Dorschner JM; Jensen MA; Chrabot BS; Kern M; Curtis JR; Danila MI; Cofield SS; Shadick N; Nigrovic PA; St Clair EW; Bingham CO; Furie R; Robinson W; Genovese M; Striebich CC; O'Dell JR; Thiele GM; Moreland LW; Levesque M; Bridges SL; Gregersen PK; Niewold TB
    Ann Rheum Dis; 2016 Oct; 75(10):1757-62. PubMed ID: 26546586
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tumor necrosis factor-α promoter -308/238 polymorphism association with less severe disease in ankylosing spondylitis is unrelated to serum TNF-α and does not predict TNF inhibitor response.
    Nossent JC; Sagen-Johnsen S; Bakland G
    J Rheumatol; 2014 Aug; 41(8):1675-82. PubMed ID: 25028373
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anti-TNF treatment response in rheumatoid arthritis patients with moderate disease activity: a prospective observational multicentre study (MODERATE).
    Ceccarelli F; Massafra U; Perricone C; Idolazzi L; Giacomelli R; Tirri R; Russo R; Pistone G; Ruscitti P; Parisi S; Sainaghi PP; Cacciapaglia F; Zullo A; Marino V; Migliore A; Valesini G
    Clin Exp Rheumatol; 2017; 35(1):24-32. PubMed ID: 27974105
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genetic variants within the TNFRSF1B gene and susceptibility to rheumatoid arthritis and response to anti-TNF drugs: a multicenter study.
    Canet LM; Filipescu I; Cáliz R; Lupiañez CB; Canhão H; Escudero A; Segura-Catena J; Soto-Pino MJ; Ferrer MA; García A; Romani L; Pérez-Pampin E; González-Utrilla A; López Nevot MA; Collantes E; Fonseca JE; Sainz J
    Pharmacogenet Genomics; 2015 Jul; 25(7):323-33. PubMed ID: 25850964
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association between TNF-α promoter -308 A/G polymorphism and rheumatoid arthritis: a meta-analysis.
    Song GG; Bae SC; Kim JH; Lee YH
    Rheumatol Int; 2014 Apr; 34(4):465-71. PubMed ID: 24306269
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Confirmation of an IRAK3 polymorphism as a genetic marker predicting response to anti-TNF treatment in rheumatoid arthritis.
    Sode J; Vogel U; Bank S; Andersen PS; Hetland ML; Locht H; Heegaard NHH; Andersen V
    Pharmacogenomics J; 2018 Jan; 18(1):81-86. PubMed ID: 27698401
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The tumor necrosis factor receptor superfamily member 1B polymorphisms predict response to anti-TNF therapy in patients with autoimmune disease: A meta-analysis.
    Chen W; Xu H; Wang X; Gu J; Xiong H; Shi Y
    Int Immunopharmacol; 2015 Sep; 28(1):146-53. PubMed ID: 26071216
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Which patients with rheumatoid arthritis, spondyloarthritis, or juvenile idiopathic arthritis receive TNF-α antagonists in France? The CORPUS cohort study.
    Saraux A; Benichou J; Guillevin L; Idbrik L; Job-Deslandre C; Sibilia J; Soudant M; Wendling D; Guillemin F
    Clin Exp Rheumatol; 2015; 33(5):602-10. PubMed ID: 26315585
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Baseline CXCL10 and CXCL13 levels are predictive biomarkers for tumor necrosis factor inhibitor therapy in patients with moderate to severe rheumatoid arthritis: a pilot, prospective study.
    Han BK; Kuzin I; Gaughan JP; Olsen NJ; Bottaro A
    Arthritis Res Ther; 2016 Apr; 18():93. PubMed ID: 27102921
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Polymorphisms at phase I-metabolizing enzyme and hormone receptor loci influence the response to anti-TNF therapy in rheumatoid arthritis patients.
    Canet LM; Sánchez-Maldonado JM; Cáliz R; Rodríguez-Ramos A; Lupiañez CB; Canhão H; Martínez-Bueno M; Escudero A; Segura-Catena J; Sorensen SB; Hetland ML; Soto-Pino MJ; Ferrer MA; García A; Glintborg B; Filipescu I; Pérez-Pampin E; González-Utrilla A; Nevot MÁL; Conesa-Zamora P; Broeder AD; De Vita S; Jacobsen SEH; Collantes-Estevez E; Quartuccio L; Canzian F; Fonseca JE; Coenen MJH; Andersen V; Sainz J
    Pharmacogenomics J; 2019 Feb; 19(1):83-96. PubMed ID: 30287909
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The influence of genetic variation in the HLA-DRB1 and LTA-TNF regions on the response to treatment of early rheumatoid arthritis with methotrexate or etanercept.
    Criswell LA; Lum RF; Turner KN; Woehl B; Zhu Y; Wang J; Tiwari HK; Edberg JC; Kimberly RP; Moreland LW; Seldin MF; Bridges SL
    Arthritis Rheum; 2004 Sep; 50(9):2750-6. PubMed ID: 15457442
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacogenomics of tumor necrosis factor antagonists in rheumatoid arthritis.
    Ranganathan P
    Pharmacogenomics; 2005 Jul; 6(5):481-90. PubMed ID: 16013998
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Change in Gait Deviation Index after anti-tumour necrosis factor-α treatment in individuals with rheumatoid arthritis: a pilot study.
    Broström EW; Esbjörnsson AC; von Heideken J; Larsson P; Wretenberg P; Iversen M
    Scand J Rheumatol; 2013; 42(5):356-61. PubMed ID: 23581251
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Assessing the cost-effectiveness of biologic agents for the management of moderate-to-severe rheumatoid arthritis in anti-TNF inadequate responders in Italy: a modelling approach.
    Cimmino MA; Leardini G; Salaffi F; Intorcia M; Bellatreccia A; Dupont D; Beresniak A
    Clin Exp Rheumatol; 2011; 29(4):633-41. PubMed ID: 21813056
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.